Amgen Inc.

A2 Biotherapeutics, Inc.

Other

Agnes Eva Hamburger

Jeonghoon Sun

Yue-Sheng Li

Mark Leo Michaels

Jing M Xu

Randy Ira Hecht

Edward John Belouski

Murielle Marie Ellison

Cen Xu

Kenneth William Walker

Zhulun Wang

Gunasekaran Kannan

Jackie Zeqi Sheng

Yi Lin Zhang

Xiaoshan Min

Murielle M Veniant-Ellison

Jie Tang

YuMei Xiong

Carl Alexander Kamb

Grant Shimamoto

Mark E Daris

Kiran Deshmukh

Breanna Diandreth

Derek Evan Piper

Bryan D Lemon

Neeraj Jagdish Agrawal

Kevin Graham

Christopher Mohr

Hong Sun

Marissa Mock

Yi Zhang

Dohan Weeraratne

Jing Xu

Yuan D Shih

Dora Toledo Warshaviak

Talar Tokatlian

Yumei Xiong

Provided are chimeric antigen receptors having the hinge, transmembrane region, and/or intracellular domain of LILRB1, or functional fragments or variants thereof. Also provided herein are cells comprising the LILRB1 based receptors, and methods of making and using same.

LILRB1-based chimeric antigen receptor

The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

Polynucleotides encoding monoclonal antibodies binding to human pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1) and methods of making thereof

The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

Methods of treating non-alcoholic steatohepatitis using FGF21 mutants

The present invention relates to monoclonal antibodies that specifically bind to human pituitary adenylate cyclase activating polypeptide (PACAP) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the monoclonal antibodies are also described.

PACAP antibodies and uses thereof

GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.

Growth differentiation factor 15 (GDF-15) polypeptides

The disclosure provides immune cells comprising a first activator receptor specific to mesothelin and a second inhibitory receptor specific to a ligand that has been lost in a mesothelin-positive cancer cell, and methods of making and using same for the treatment of cancer.

Compositions and methods for treating mesothelin positive cancers

Methods for treating a headache condition using anti-human PAC1 antibodies or antigen-binding fragments thereof

The invention provides methods for treating non-alcoholic steatohepatitis (NASH) using FGF21 mutant polypeptides.

Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.

Growth differentiation factor 15 (GDF-15) constructs

Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine and cluster headache.

Human PAC1 antibodies

PAC1 antibodies and uses thereof

Growing community of inventors

Newbury Park, CA, United States of America

Agnes Eva Hamburger